18860-78-1

Basic information

• Product Name: DIAMINOIMINOBENZENE HYDROIODIDE
• Synonyms: N''-Phenylguanidine nitrate;NITRIC ACID COMPOUND WITH N''-PHENYLGUANIDINE (1:1);DIAMINOIMINOBENZENE HYDROIODIDE;2-Phenylguanidine nitrate;2-Phenylguanidine nitrate 99%;N''-Phenylguanidine nitrate , 97+%;Phenylguanidine nitrate;2-phenylguanidine
• CAS NO: 18860-78-1
• Molecular Formula: C₇H₉N₃*HNO₃
• Molecular Weight: 198.18
• Product Categories: Phenyls & Phenyl-Het;Phenyls & Phenyl-Het
• Mol File: 18860-78-1.mol
• Article Data: 8

Chemical Properties

• Melting Point: 122 °C
• Boiling Point: 290.5 °C at 760 mmHg
• Flash Point: 129.5 °C
• Appearance: /
• CAS DataBase Reference: DIAMINOIMINOBENZENE HYDROIODIDE(CAS DataBase Reference)
• NIST Chemistry Reference: DIAMINOIMINOBENZENE HYDROIODIDE(18860-78-1)
• EPA Substance Registry System: DIAMINOIMINOBENZENE HYDROIODIDE(18860-78-1)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 18860-78-1(Hazardous Substances Data)

Usage

General Description

DIAMINOIMINOBENZENE HYDROIODIDE is a chemical compound with the molecular formula C6H9N3?HI. It is a salt compound that is commonly used as a reagent in chemical synthesis, particularly in the production of pharmaceuticals and dyes. DIAMINOIMINOBENZENE HYDROIODIDE is an important intermediate in organic chemistry and is used in the preparation of various nitrogen-containing compounds. It is a white to off-white crystalline solid that is soluble in water and other polar solvents. As a chemical reagent, it is known for its ability to facilitate reactions involving amines and other organic compounds.

Upstream product

• 420-04-2 CYANAMID 
• 62-53-3 aniline 
• 156-62-7 calcium cyanamide 
• 542-15-4 anilinium nitrate 

Downstream Products

• 22713-99-1 N-phenyl-N'-phenylcarbamimidoyl-thiourea 
• 1383073-97-9 4-(1-methyl-1H-benzimidazol-2-yl)-N-phenylpyrimidin-2-amine 

Relevant articles and documents

7-(2-anilinopyrimidin-4-yl)-1-benzazepin-2-ones designed by a “cut and glue” strategy are dual aurora a/vegf-r kinase inhibitors

Although overexpression and hyperactivity of protein kinases are causative for a wide range of human cancers, protein kinase inhibitors currently approved as cancer drugs address only a limited number of these enzymes. To identify new chemotypes addressing alternative protein kinases, the basic structure of a known PLK1/VEGF-R2 inhibitor class was formally dissected and reassembled. The resulting 7-(2-anilinopyrimidin-4-yl)-1-benzazepin-2-ones were synthesized and proved to be dual inhibitors of Aurora A kinase and VEGF receptor kinases. Crystal structures of two representatives of the new chemotype in complex with Aurora A showed the ligand orientation in the ATP binding pocket and provided the basis for rational structural modifications. Congeners with attached sulfamide substituents retained Aurora A inhibitory activity. In vitro screening of two members of the new kinase inhibitor family against the cancer cell line panel of the National Cancer Institute (NCI) showed antiproliferative activity in the single-digit micromolar concentration range in the majority of the cell lines.

Crystal structure of liganded cFMS kinase domain

A crystal structure of the cfms kinase domain, co-crystal structure with a bound small molecule, as well as methods of using the same in the discovery of cfms inhibitors and in the treatment of diseases mediated by inappropriate cfms activity.

A novel series of potent and selective IKK2 inhibitors

A novel series of aminopyrimidine IKK2 inhibitors have been developed which show excellent in vitro inhibition of this enzyme and good selectivity over the IKK1 isoform. The relative potency and selectivity of these compounds has been rationalized using QSAR and structure-based modelling.